BIOLARGO, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $7.8M | $17.8M | $12.2M | $5.9M | $2.5M | $2.4M | $1.9M |
| Cost of Revenue | — | $4.4M | $9.9M | $6.1M | $3.0M | $1.4M | $1.2M | $945.0K |
| Gross Profit | — | $3.4M | $7.9M | $6.2M | $2.9M | $1.1M | $1.2M | $916.0K |
| Gross Margin | — | 43.9% | 44.2% | 50.3% | 48.6% | 43.6% | 50.5% | 49.2% |
| Operating Expenses | ||||||||
| Research & Development | — | $2.6M | $2.9M | $2.3M | $1.3M | $1.4M | $1.3M | $1.5M |
| SG&A Expense | — | $11.8M | $9.3M | $8.1M | $6.7M | $6.2M | $7.5M | $6.1M |
| Operating Income | — | $-14.9M | $-4.3M | $-4.6M | $-5.4M | $-6.8M | $-7.6M | $-6.7M |
| Operating Margin | — | -191.3% | -24.4% | -37.4% | -91.6% | -267.8% | -311.8% | -359.8% |
| Interest Expense | — | $540.0K | $71.0K | $91.0K | $53.0K | $234.0K | $1.9M | $4.0M |
| Pretax Income | — | $-15.2M | $-4.3M | — | — | — | — | — |
| Income Tax Expense | — | — | $0 | $0 | — | — | — | — |
| Net Income | — | $-15.2M | $-4.3M | $-4.6M | $-5.1M | $-6.9M | $-9.7M | $-11.4M |
| Net Margin | — | -195.6% | -24.5% | -38.0% | -87.2% | -272.4% | -398.8% | -614.7% |
| EPS (Basic) | — | $-0.04 | $-0.01 | $-0.01 | $-0.02 | $-0.03 | $-0.05 | $-0.08 |
| EPS (Diluted) | — | — | — | — | — | $-0.03 | $-0.05 | $-0.08 |
| Shares Outstanding (Basic) | 320.9M | 307.0M | 298.1M | 286.0M | 268.3M | 247.2M | 196.0M | 152.1M |
| Shares Outstanding (Diluted) | 320.9M | 307.0M | 298.1M | 286.0M | 268.3M | 247.2M | 196.0M | 152.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |